Selective HIF-2α Inhibitor Aryl Ethers for Renal Cell Carcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly renal cell carcinoma, face challenges in effectively inhibiting the hypoxic response pathway driven by HIF-2α proteins, which are crucial for tumor progression and resistance to chemotherapy and radiation.
Innovation Solution
A compound of Formula I or its pharmaceutically acceptable salt, which selectively inhibits HIF-2α activity, is administered to reduce the expression of HIF-2α and its regulated genes, thereby targeting renal cell carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If broad inhibition of the hypoxic response pathway through direct targeting of HIF-α proteins is pursued, then multiple cancer fronts can be attacked simultaneously, but selective inhibition of HIF-2α without affecting HIF-1α remains challenging
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target HIF-2α while sparing HIF-1α. The chemical structure incorporates specific substituents (R1-R5 groups) that create differential binding affinity for HIF-2α's PAS domain, enabling selective inhibition at the molecular level while maintaining the broader therapeutic effect of hypoxic pathway blockade.
2Reliability
If HIF-2α activity is inhibited to reduce tumor progression and chemotherapy resistance, then patient prognosis may improve, but off-target effects on other HIF-regulated genes could occur
Solution Approach 1:
The patent utilizes parameter changes by systematically varying chemical parameters (substituents at R1-R5 positions) to optimize the compound's binding specificity. This structural optimization ensures high affinity for HIF-2α while maintaining selectivity that prevents unwanted effects on other HIF-regulated genes, thereby improving therapeutic reliability.
3Productivity
If selective HIF-2α inhibition is achieved through compound design, then tumor size reduction can be accomplished, but the complexity of synthesizing and characterizing these specialized compounds increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules (R1-R5 substituents on the core scaffold). This modular approach allows independent optimization of each region for specific binding interactions with HIF-2α, facilitating systematic synthesis and characterization while maintaining high tumor efficacy.
Data Source
AI summary
The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.